Guyer William sold $419K of CORT
Guyer William (Chief Development Officer) sold 3,700 shares of CORCEPT THERAPEUTICS INC (CORT) at $113.12 ($0.42M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the disclosed sale size, price, and post-transaction holdings; there is no accompanying corporate event that would reset valuation assumptions.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low-impact.
What to watch
Insider sales can be driven by diversification, tax planning, or pre-scheduled liquidity needs; without additional context, the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported as an open-market sale under a Rule 10b5-1 plan.
Ticker impact
Corcept Therapeutics Form 4 shows insider William Guyer sold 3,700 shares at $113.1248 on 2026-08-04 under a 10b5-1 plan.
Likely limited near-term impact; any effect is typically sentiment-driven and short-lived.
The filing is a scheduled 10b5-1 open-market sale, and the article provides no accompanying company-specific news (earnings, guidance, trials, deals, or enforcement).
Market effects
No clear sector read-through because the disclosure lacks new clinical, regulatory, or product information.
None indicated; this is a single-company insider transaction.
None indicated.
Counterpoint
A 10b5-1 sale can be purely mechanical and may not signal reduced confidence; traders should avoid over-weighting it versus fundamentals.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction disclosure.
- insiderWilliam Guyer
Chief Development Officer who sold shares under a pre-arranged 10b5-1 plan.
